Application of nanomedicine in radiotherapy sensitization
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Radiation therapy is an important component of cancer treatment. As research in radiotherapy techniques advances, new methods to enhance tumor response to radiation need to be on the agenda to enable enhanced radiation therapy at low radiation doses. With the rapid development of nanotechnology and nanomedicine, the use of nanomaterials as radiosensitizers to enhance radiation response and overcome radiation resistance has attracted great interest. The rapid development and application of emerging nanomaterials in the biomedical field offers good opportunities to improve the efficacy of radiotherapy, which helps to promote the development of radiation therapy and will be applied in clinical practice in the near future. In this paper, we discuss the main types of nano-radiosensitizers and explore their sensitization mechanisms at the tissue level, cellular level and even molecular biology and genetic level, and analyze the current status of promising nano-radiosensitizers and provide an outlook on their future development and applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321 · cited 1×
“More importantly, Hf is a high Z atom (Z=72), so it can be used as a radiosensitizer (90), which can be achieved by physical mechanisms (93, 94).”
BackgroundVegt, E., de Jong, M., Wetzels, J. F. M., Masereeuw, R., Melis, M., Oyen, W. J. G., Gotthardt, M., & Boerman, O. C. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.075101 · Cited by 334
Werner, M. E., Cummings, N. D., Sethi, M., Wang, E. C., Sukumar, R., Moore, D. T., & Wang, A. Z. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.009 · Cited by 267
Bonvalot, S., Le Pechoux, C., De Baere, T., Kantor, G., Buy, X., Stoeckle, E., Terrier, P., Sargos, P., Coindre, J. M., Lassau, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1297 · Cited by 243
Application of nanoparticles on diagnosis and therapy in gliomas.
Hernández-Pedro, N. Y., Rangel-López, E., Magaña-Maldonado, R., de la Cruz, V. P., Santamaría del Angel, A., Pineda, B., & Sotelo, J. (2013) · BioMed Research International · doi:10.1155/2013/351031 · Cited by 84 · cited 1×
“Due to the EPR effect, nanomaterials of the right size can accumulate in tumor tissues and improve the sensitivity of tumors to radiotherapy through passive targeting (44, 45).”
Background
Cited by
Application of High-Z Nanoparticles to Enhance Current Radiotherapy Treatment
Jackson, N., Cecchi, D., Beckham, W., & Chithrani, D. B. (2024) · Molecules · doi:10.3390/molecules29112438 · Cited by 52
“Various high-atomic-number (Z) NPs have shown promising radiosensitizing effects and can be functionalized in ways such that they preferentially target tumor cells in comparison with normal tissue [10].”
BackgroundColak, B., & Ertas, Y. N. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c17024 · Cited by 50
Mostafavi, M., Ghazi, F., Mehrabifard, M., Alivirdiloo, V., Hajiabbasi, M., Rahimi, F., Mobed, A., Taheripak, G., Ramezani Farani, M., Huh, Y. S., et al. (2025) · Strahlentherapie und Onkologie · doi:10.1007/s00066-024-02301-y · Cited by 16
Metadata
- Authors
- Song, X., Sun, Z., Li, L., Zhou, L., & Yuan, S.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2023-02-15
- Volume
- 13
- Pages
- 1088878-1088878
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W4320919271
- Cited by
- 51
- References
- 6
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Application of nanomedicine in radiotherapy sensitization. https://app.cochat.ai/papers/10.3389/fonc.2023.1088878
- The paper
- Song, X., Sun, Z., Li, L., Zhou, L., & Yuan, S. (2023). Application of nanomedicine in radiotherapy sensitization. Frontiers in Oncology. https://doi.org/10.3389/fonc.2023.1088878
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.